Novartis Ag (NVS) EBT Growth (1y) (2010 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
156.08% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-56.06% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-37.45% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-159.29% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
5.63% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
56.46% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
13.82% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
9.05% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
17.96% |
| Dec 31, 2024 |
34.19% |
| Jun 30, 2024 |
43.64% |
| Dec 31, 2023 |
10.25% |
| Jun 30, 2023 |
-47.46% |
| Mar 31, 2023 |
-12.77% |
| Dec 31, 2022 |
-20.90% |
| Sep 30, 2022 |
-9.19% |
| Jun 30, 2022 |
-14.97% |
| Mar 31, 2022 |
15.76% |
| Dec 31, 2021 |
21.33% |
| Sep 30, 2021 |
6.29% |
| Jun 30, 2021 |
6.88% |
| Mar 31, 2021 |
164.95% |
| Mar 31, 2020 |
-61.12% |
| Mar 31, 2019 |
-20.41% |
| Dec 31, 2018 |
-5.46% |
| Sep 30, 2018 |
0.00% |
| Jun 30, 2018 |
255.03% |
| Mar 31, 2018 |
19.89% |
| Dec 31, 2017 |
-93.34% |
| Sep 30, 2017 |
11.17% |
| Jun 30, 2017 |
313.39% |
| Mar 31, 2017 |
182.70% |
| Dec 31, 2016 |
1,959.36% |
| Sep 30, 2016 |
242.86% |
| Mar 31, 2016 |
35,645,438.73% |
| Dec 31, 2015 |
67,631,003.07% |
| Sep 30, 2015 |
27,353,363.59% |
| Mar 31, 2015 |
-23.11% |
| Sep 30, 2012 |
-0.19% |
| Jun 30, 2012 |
7.31% |
| Mar 31, 2012 |
-26.09% |
| Dec 31, 2011 |
98.21% |
| Sep 30, 2011 |
-12.78% |
| Jun 30, 2011 |
19.62% |
| Mar 31, 2011 |
-79.80% |
| Dec 31, 2010 |
-100.00% |
| Sep 30, 2010 |
-75.19% |
| Jun 30, 2010 |
-80.80% |
| Mar 31, 2010 |
53.75% |
